ACP does not support PQRS 90: “Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Treatment.” This measure assumes that all therapeutic regimens have teratogenicity. Because treatment for Hepatitis C is changing rapidly, this may not be the case in the future. In addition, there is no reason why men with Hepatitis C need to be counseled about contraception prior to starting antiviral treatment. There is no evidence that these drugs are teratogenic if a man is taking them and he impregnates a woman.

Date Reviewed: July 26, 2014